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The aim of this study was to investigate the effects of pentoxifylline (PTX) on the production of TNF-a, IL-ID, IL-6 
and GM-CSF by lipopolysaccharide (LPS)-stimulated alveolar macrophages (AM). 
AM and peripheral blood monocytes (PBM) from 10 patients were cultured for 24 h in the presence of LPS 
(10 pg ml- ‘) and PTX at concentrations of 2.0 mM, 1.0 mM, 0.5 mM, 0.1 mM and 0.01 mM. 
TNF-a and GM-CSF were measured from the culture supernatants of both the AM and PBM from all 10 patients 
and IL-l/3 and IL-6 from the culture supernatants of the AM from five patients. 
The TNF-a production by AM was significantly suppressed in the presence of PTX at concentrations of 2.0 and 
1-O mM, while production of IL-lp, IL-6 and GM-CSF remained unaffected. In PBM cultures, PTX significantly 
suppressed the production of TNF-a and GM-CSF, at all tested concentrations. 
The present study provides evidence that PTX selectively suppresses the production of TNF-a by LPS-stimulated 
AM and may have a role in the treatment of lung diseases where TNF-a is involved. The mode of administration of 
PTX should take into account the suppressive effect of this drug on GM-CSF production by PBM. 
RESPIR. MED. (1999) 93, 52-57 
Introduction 
Activated alveolar macrophages participate in a variety of 
inflammatory and immunological pulmonary disorders by 
producing and releasing a large panel of cytokines (1). 
Among these TNF-a, IL-l and IL-6 have a central role in 
the development and progression of acute and chronic lung 
injury (2). Recent studies have also shown that the haemo- 
poietic cytokine GM-CSF has a pivotal place in maintain- 
ing normal pulmonary homeostasis and function (3,4,5) 
and is involved in several pathological processes underlying 
respiratory diseases (6,7). Furthermore, recent data support 
the view that IL-6 and some ILd-regulated acute phase 
proteins predominantly have an anti-inflammatory and 
immunosuppressive effect, contributing to the amelioration 
of acute and chronic inflammatory processes (8). 
Pentoxifylline (PTX) is a 3,7-dimethyl-I-(5-oxohexyl)- 
xanthine that inhibits the action of phosphodiesterase and 
is used clinically for the treatment of vascular diseases, 
especially conditions with defective regional microcircu- 
lation (9). PTX increases platelet deaggregation and the 
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production of vasodilatory prostaglandins and inhibits 
LPS-induced leukocyte adhesion (9,lO). Several studies 
on septic patients have drawn attention to the anti- 
inflammatory activity of PTX (11,12,13). In addition, the 
beneficial effect of PTX on lung reperfusion injury has been 
tested in lung transplant patients (14). Some of these 
actions have been attributed to the suppressive effect of 
PTX on the production of TNF-a by monocytes, alveolar 
macrophages and interstitial pulmonary macrophages 
(13,15,16). One recent study suggests that PTX may modu- 
late the production of a broader spectrum of cytokines 
produced by peripheral blood lymphocytes (17). However, 
there are no data regarding the effects of PTX on the 
production of other pro-inflammatory cytokines and 
colony-stimulating factors by AM. We performed this 
experiment in order to investigate the effects of PTX on 
the production of TNF-a, IL-l/3, IL-6 and GM-CSF by 
activated alveolar macrophages. 
Material and Methods 
Ten patients with an indication for bronchoalveolar lavage 
(BAL) were included in our study. The mean age of the 
study population was 47 years (range 34-57 years). There 
were nine men and one woman. Eight were smokers and 
two ex-smokers. Three patients had lung cancer, one 
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cryptogenic fibrosing alveolitis, one drug-induced inter- 
stitial lung disease, and five chronic obstructive lung 
disease. 
BAL was performed with a flexible fibreoptic broncho- 
scope with local xylocaine anestheia. Normal saline (5 20 ml 
aliquots) was instilled in the lingula or in the right middle 
lobe bronchus and the recovered fluid was filtered through a 
sterile gauze. The total cell count was determined using a 
Neubauer chamber. Cell differentials were made from 
smears stained with May-Griinwald-Giemsa by counting at 
least 600 cells. A trypan blue exclusion test for cell viability 
was performed and viability was found to be over 95%. 
The general characteristics of BAL fluid in the 10 patients 
were the following: BAL volume (recovered): 55 ml, total 
cell count: 15.8 * 2.2 x 106, total cells per ml of recovered 
BAL fluid: 0.250 x 103. Cell types were: macrophages: 
82 f 8%, lymphocytes: 15 * 7%, polymorphonuclear cells 
3 & 4%. 
BAL fluid was centrifuged at 400g for 10 min, and the 
cell pellet was washed three times with sterile PBS. The 
BAL cells were resuspended at a concentration of 0.5 x 
lo6 cells ml- ’ in complete culture medium consisting 
of RPMI-1640 (Gibco, Grand Island, NY, U.S.A.), 
100 U ml - ’ penicillin, 100 pg ml - ’ streptomycin, 2 mM 
L-glutamine and 2% of heat-inactivated fetal calf serum 
(Gibco). 
The mononuclear cell (MNC) fraction was obtained by 
gradient centrifugation (400 g 30 min - ‘) of heparinized 
blood, diluted with sterile PBS (1 part blood, 1 part PBS) 
over Ficoll-Hypaque. MNC were washed twice in PBS. 
This protocol provides a population of MNC consisting of 
approximately 20% monocytes and 80% lymphocytes, as 
determined by light microscopy. 
The cells were adjusted to 0.8 x lo6 cells ml- ’ in the 
above described culture medium containing 5% of heat 
inactivated fetal calf serum. 
The cell suspension was seeded in 24-well plastic tissue 
culture plates (Falcon, Oxnard, CA), and the AM and 
MNC were purified by adherence to plastic plates for 
60 min at 37°C in 5% CO, humidified air. The plastic plates 
were then vigorously rinsed with RPM1 to remove the 
nonadherent cells. The adherent cells were then incubated 
for 24 h with complete medium only, complete medium 
with lipopolysaccharide (LPS; Escherichia coli 055:B5 
Sigma, Munich, Germany), (IOpg ml - ‘), complete 
medium with LPS and pentoxifylline (Hoechst Pharmaceu- 
tical, Germany) at concentrations of 2, 1, 0.5, 0.1 and 
0.01 mM. Cell viability was checked again and was found to 
be over 95%. The supernatants of the cultured cells were 
harvested and stored frozen at - 70°C. 
In our study we used LPS at 1Opg ml - ’ because at this 
concentration LPS stimulates human blood monocytes and 
alveolar macrophages for maximum TNF-a, IL-l, and IL-6 
production, without affecting survival of cultured cells 
(18,19). 
IL-l/?, IL-6, TNF-a and GM-CSF from culture super- 
natants were measured using ELISA from a commercial kit 
(ENDOGEN, Cambridge, U.S.A.). With this method, the 
lower detection values were: GM-CSF, 2 pg ml - ‘; TNF-a, 
5pgml-‘; II-la and IL-6, 1 pgml-‘. 
Statistical Analysis $20 
A paired Student’s t-test was performed when data showed 
a normal distribution. Non-parametric data were analysed 
by the non-parametric Wilcoxon signed-rank test. Differ- 
ences were considered significant for values of PcO.02 
(values are indicated as mean+~~~ for parametric tests and 
as median+~~~ for non-parametric tests). 
Results 
Our results are shown in Table 1 and Fig. 1. 
TNF-a production by AM after stimulation by IOpg of 
LPS was statistically significantly reduced at the 2.0 and 
1.0 mM concentrations of PTX. At these concentrations the 
TNF-a production by AM fell to 22 and 57%, respectively, 
of the levels produced by AM after LPS stimulation alone. 
The TNF-a production by MNC was also reduced by PTX, 
at all tested concentrations. This inhibitory effect was 
observed even at concentrations as low as 0.01 mM. 
There was no significant reduction of GM-CSF produc- 
tion by AM. At PTX concentrations of 2.0 mM, production 
was 91% of the baseline. In contrast, GM-CSF production 
in MNC cultures was remarkably reduced by PTX at all 
tested concentrations. At 2.0 mM, GM-CSF production was 
23% and at 0.01 mM it was 45% of the maximum GM-CSF 
production by MNC. 
The production of IL-l/? and IL-6 by LPS-stimulated 
AM was not affected by PTX at all tested concentrations. 
In order to test the possibility that the blocking effect of 
PTX on TNF-a and GM-CSF production by MNC may be 
due to apoptosis, we measured apoptosis in three exper- 
iments using 24-h cultures of MNC with complete medium, 
complete medium with LPS (10~8 ml - ‘), and complete 
medium with LPS and PTX at a concentration of 2 mM. 
Apoptotic monocytes were measured with a Coulter Epics 
(Coulter Electronics Ltd, Luton, U.K.) flow cytometer with 
the TUNEL test. No differences in apoptosis were found at 
all three experiments under the tested conditions (Table 2, 
Fig. 2). 
Discussion 
In this study we found that the production of IL-lb, B-6 
and GM-CSF by AM was unaffected by PTX, whereas 
TNF-a production was markedly reduced at relatively high 
concentrations (2 mM and 1 mM PTX). In contrast, PTX 
suppressed both TNF-a and GM-CSF production in MNC 
cultures at all tested concentrations. 
The selective inhibitory effect of PTX on TNF-a produc- 
tion is supported by the results of other studies. Thus, 
Semmler et al. (20) reported the selective suppression of 
TNF-a production as compared to IL-lb by PTX in LPS 
activated human MNC. Bernard et al. (21) also reported on 
the selective inhibition of PTX on TNF-a production by 
endothelial cells under LPS stimulation as compared to 
IL-6. Zeni et al. (12), studying the effects of continuous i.v. 
infusion of PTX on the serum levels of TNF-a, IL-6 and 
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FIG. 1. Mean values of GM-CSF, TNF-a, IL-1B and IL-6 
in alveolar macrophage (AM) and mononuclear cell 
(MNC) cultures. Groups: (A) Complete medium (CM), 
(B) CM and lipopolysaccharide (LPS) 10 pug ml -’ (C) 
CM with LPS and pentoxifylline (PTX) 2.0 mM, (D) CM 
with LPS and PTX 1.0 mM, (E) CM with LPS and PIX 
0.5 mM, (F) CM with LPS and PTX 0.1 mM, (G) CM 
with LPS and PTX 0.01 mM. (+, GMCSF-(BAL); 
n , TNF-(BAL); A, IL-l/3-(BAL); x , IL-6-(BAL); 
*, GMCSF-(PBM); l , TNF-(PBM)). 
TABLE 2. Apoptosis of mononuclear cells (MNC) in 24-h 
cultures, expressed as the percentage of the total cell 
number 
Experiment no. A B C 
1 8.2% 7.4% 8.8% 
2 7.8% 7.5% 57% 
3 9.3% 8.1% 5.8% 
A: Apoptosis in 24-h MNC cultures with CM. B: Apoptosis 
in 24-h MNC cultures with CM+LPS (10 ,ug ml - ‘), C: 
Apoptosis in 24-h MNC cultures with CM+LPS+PTX 
(2 rnM). 
IL-8 in patients with septic shock, found a selective decrease 
of TNF-a whereas the levels of the other two cytokines 
remained unaffected. 
PTX is a phosphodiesterase (PDE) inhibitor and its 
TNF-a suppressive effect is mediated through an increased 
cellular concentration of CAMP (20). MNC contain the 
PDE4 isoenzyme (22), whilst AM express PDEI, PDES and 
PDE3 activity (23). Since PTX suppresses TNF-a produc- 
tion in both MNC and AM, its action as a PDE inhibitor 
appears to be non-specific. Furthermore the unimpaired 
production of IL-l, IL-6 and GM-CSF by AM in the 
presence of PTX suggests that these cytokines may be 
CAMP independent. It has been shown that phospho- 
diestarase inhibitors and CAMP analogues block the 
accumulation of cachectinlTNF-a mRNA (24). This 
specific and comparatively selective effect of PTX on 
TNF-a is probably based on decreased transcription of the 
cachectinlTNF-a gene. Han ef al. (25), studying the signal- 
ling pathways of PTX and dexamethasone on TNF-a 
production by macrophages under LPS stimulation, found 
that PTX strongly inhibits the accumulation of cachectim 
TNF-a mRNA, but has no effect upon the reporter mRNA 
translation. In contrast, dexamethasone exerts a strong 
inhibitory effect upon translational derepression and 
weakly inhibits the accumulation of cachectin mRNA. 
In our study different concentrations of PTX were 
required to suppress the production of TNF-a by LPS- 
stimulated AM and MNC. In AM cultures, a much higher 
concentration of PTX was required to inhibit the produc- 
tion of TNF-a than in MNC cultures. AM, on a per-cell 
basis, are apparently producing higher amounts of TNF-u 
than MNC (19) and thus higher concentrations of PTX are 
probably needed to exert an inhibitory effect on TNF-a 
production by AM. 
In our study we also found that PTX inhibited the pro- 
duction of GM-CSF by MNC but not by AM. An inhibi- 
tory effect of PTX on GM-CSF production by PBM, either 
in cultures or in vivo, is also supported by previous studies 
by Tsujino et al. (26) and Heinkelein et al. (27). 
This difference is probably due to the process of differ- 
entiation of human monocytes to aleveolar macrophages. 
Strieter et al. (28) found that prostaglandin E2 (PGE2) 
reduced TNF-a production in blood monocytes but not 
in alveolar macrophages and that a lOOO-fold increase of 
PGE2 was necessary to induce a 50% suppression of the 
maximum response of AM as compared to PBM. Similarly 
Standiford et al. (29) have also demonstrated a differential 
responsiveness of PGE2 on the production of IL-8 by 
human PBM and AM. 
The selective effect of PTX on TNF-a suppression and 
the unaffected production of IL-6 and GM-CSF by AM, as 
shown in our experiments, support the view that PTX may 
have a role as an immunomodulator drug in the treatment 
of lung diseases where TNF-a is involved. Furthermore, 
PTX can inhibit apoptosis, programmed cell death, of 
human neutrophils, an action which can be of value in 
protection of lungs from acute injury (30). Considering that 
GM-CSF has a critical role in host defence and that the 
priming effect of GM-CSF on neutrophils is well preserved 
in the presence of PTX (31,32), it seems likely that the 
anti-inflammatory action of PTX would not affect the lung 
immune defence. One should, however, take into account 
the suppressive action of PTX on GM-CSF production by 
MNC, especially when PTX is administered i.v. 
The serum levels of PTX in patients receiving this 
drug at currently recommended doses (approximately 
20mgkgg’ day - ‘) are generally less than 1 ,uM (33), and 
inhibition of inflammatory lung injury models in vivo has 
been achieved with much higher infusion rates (20 mg kg- ’ 
bolus and 6 mg kg - ’ h - ‘) delivered i.v. (34). Therefore, 
the high concentrations needed for PTX to exert its bene- 
ficial effects probably preclude its systemic administration 
in high doses because of possible adverse effects. 
Based on these considerations, we propose that a possible 
effective route of administration of relatively high concen- 
trations of PTX in cases of lung injury, in which TNF-a 
production by activated AM is taking place, is via 
inhalation preparations (aerosols). 
Further studies are needed to evaluate the efficacy of the 
iv. administration as compared with the local application 
by aerosol of PTX in lung injury models. 
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FIG. 2. Apoptosis in 24-h MNC cultures. (a) MNC culture with complete medium (CM). (b) MNC culture with 
CM+LPS (lOpug ml-‘). (c) MNC culture with CM+LPS+PTX at 2 mu. 
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